Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABSW) Equity Average (2021 - 2025)

SAB Biotherapeutics' Equity Average history spans 5 years, with the latest figure at $158.3 million for Q4 2025.

  • For Q4 2025, Equity Average rose 403.51% year-over-year to $158.3 million; the TTM value through Dec 2025 reached $158.3 million, up 403.51%, while the annual FY2025 figure was $88.7 million, 113.12% up from the prior year.
  • Equity Average reached $158.3 million in Q4 2025 per SABSW's latest filing, up from $88.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $158.3 million in Q4 2025 to a low of $16.7 million in Q2 2025.
  • Average Equity Average over 5 years is $43.2 million, with a median of $36.7 million recorded in 2021.
  • The largest YoY upside for Equity Average was 403.51% in 2025 against a maximum downside of 66.22% in 2025.
  • A 5-year view of Equity Average shows it stood at $36.8 million in 2021, then decreased by 16.23% to $30.8 million in 2022, then increased by 17.63% to $36.3 million in 2023, then fell by 13.35% to $31.4 million in 2024, then surged by 403.51% to $158.3 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Equity Average are $158.3 million (Q4 2025), $88.5 million (Q3 2025), and $16.7 million (Q2 2025).